Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity.
He H, Jiang H, Chen Y, Ye J, Wang A, Wang C, Liu Q, Liang G, Deng X, Jiang W, Zhou R. · 2018
Read Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. by He H, Jiang H, Chen Y, Ye J, Wang A, Wang C, Liu Q, Liang G, Deng X, Jiang W, Zhou R. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6026158.txt.
Introduction
He and co-authors identify the target of a herbal compound. Their research article appeared in Nature Communications. The compound is oridonin, from a Chinese medicinal herb. It was long known to calm inflammation. Its direct target in the body was unknown.
The team show oridonin blocks the NLRP3 inflammasome. That protein complex drives many chronic inflammatory diseases. Oridonin forms a lasting bond with NLRP3. The bond stops a partner protein from joining it. The complex then cannot assemble or switch on. In mouse models, oridonin helped against peritonitis. It also helped in gouty arthritis and type 2 diabetes. Readers get a lead compound for new anti-inflammatory drugs.
Catalog record
| CREATOR | He H, Jiang H, Chen Y, Ye J, Wang A, Wang C, Liu Q, Liang G, Deng X, Jiang W, Zhou R. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity By Hongbin He, Hua Jiang, Yun Chen, Jin Ye, Aoli Wang, Chao Wang, Qingsong Liu, Gaolin Liang, Xianming Deng, Wei Jiang, Rongbin Zhou Published in: Nature Communications DOI: 10.1038/s41467-018-04947-6 ABSTRACT Oridonin (Ori) is the major active ingredient of the traditional Chinese medicinal herb Rabdosia rubescens and has anti-inflammatory activity, but the target of Ori remains unknown. NLRP3 is a central component of NLRP3 inflammasome and has been involved in a wide variety of chronic inflammation-driven human diseases. Here, we show that Ori is a specific and covalent inhibitor for NLRP3 inflammasome. Ori forms a covalent bond with the cysteine 279 of NLRP3 in NACHT domain to block the interaction between NLRP3 and NEK7, thereby inhibiting NLRP3 inflammasome assembly and activation. Importantly, Ori has both preventive or therapeutic effects on mouse models of peritonitis, gouty arthritis and type 2 diabetes, via inhibition of NLRP3 activation. Our results thus identify NLRP3 as the direct target of Ori for mediating Ori’s anti-inflammatory activity. Ori could serve as a lead for developing new therapeutics against NLRP3-driven diseases. INTRODUCTION Oridonin (Ori), a bioactive ent-kaurane diterpenoid, is the major active constituent of Rabdosia rubescens, which has been widely used in traditional Chinese medicine1,2. Ori has shown considerable anticancer activities, which include cell cycle arrest, apoptosis induction, and angiogenesis suppression, but the relatively moderate potency and imprecise mechanisms of action have greatly hindered its clinical applications for the treatment of cancer3,4. Besides their antitumor activity, Rabdosia rubescens and Ori have also possessed anti-inflammatory activity. In China, Rabdosia rubescens is a commonly available over-the-counter (OTC) herbal medicine for the treatment of inflammatory diseases5,6. Ori has been reported to inhibit NF-κB or MAPK activation to suppress the release of proinflammatory cytokines, such as tumor necrosis factor (TNF)-α and interleukin (IL)-67–9. Moreover, Ori has also exhibited anti-inflammatory activity and protective role in colitis, sepsis, and neuroinflammation10–13. Although the anti-inflammatory activity of Ori is emerging, the underlying mechanisms and direct target are unknown. NLRP3 inflammasome is a multiple protein complex composed of innate immune sensor NLRP3, ASC, and caspase-114–17. The assembly of this complex results in the activation of caspase-1, which promotes the cleavage of pro-IL-1β and pro-IL-18 to produce mature and functional IL-1β and IL-1818,19, so it plays a central role in innate immunity and inflammation. NLRP3 can be activated by many different stimuli including both danger-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs)14–16,18. These stimuli seem to converge on three main processes intracellular ionic fluxes, ROS generation, and lysosomal damage to activate NLRP3 inflammasome, but the precise mechanism of NLRP3 activation is still unclear14–16,18. In addition, the aberrant NLRP3 inflammasome activation contributes to the progress of several human diseases, such as type 2 diabetes (T2D), atherosclerosis, Gout, and neurodegenerative diseases20–26. Moreover, several NLRP3 inflammasome inhibitors have been reported to exert beneficial effects for NLRP3-related diseases in animal models27–33. Some herbs used in traditional Chinese medicine have shown good anti-inflammatory activity and beneficial effects on inflammatory diseases34, but the complex composition and unclear pharmacology limit their clinical application. In this study, we show that Ori can target NLRP3 to exert its anti-inflammatory activity. On covalently binding to Cys279, Ori blocks the NLRP3–NEK7 interaction and the subsequent NLRP3 inflammasome assembly and activation, leading to an effective suppression of NLRP3-related diseases. RESULTS Ori specifically inhibits NLRP3 inflammasome activation To test whether oridonin (Ori) could block NLRP3 activation, we examined the impact of Ori on caspase-1 activation and IL-1β secretion (Fig. 1a). Ori exhibited dose-dependent inhibitory effects on caspase-1 cleavage, IL-1β secretion, and cell death when treated with nigericin at the doses of 0.5–2 μM in lipopolysaccharides (LPS)-primed bone marrow–derived macrophages (BMDMs), but had no effects on inflammasome-independent cytokine TNF-α production (Fig. 1b–d and Supplementary Fig. 2A). Treatment with Ori also inhibited caspase-1 activation and IL-β release stimulated by other NLRP3 agonists, including monosodium urate crystals (MSU), ATP or cytosolic LPS (cLPS) (Fig. 1e, f and Supplementary Fig. 2B, C)15,35, suggesting Ori as a broad-spectrum inhibitor of NLRP3 inflammasome. We also tested whether Ori was working for human cells. LPS-induced caspase-1 activation and IL-1β secretion in human peripheral blood mononuclear cells (PBMCs) could also be suppressed by Ori (Fig. 1g, h). In contrast, Ori had no effects on TNF-α production (Fig. 1i). The same results were obtained in PBMCs from other three donors (Supplementary Fig. 1). We also found that Ori could not suppress NLRC4 or AIM2 inflammasome activation induced by Salmonella typhimurium (Salmonella) infection or poly A:T transfection, respectively (Supplementary Fig. 2D–G).Fig. 1Ori blocks NLRP3 activation. a Ori structure. b BMDMs were primed with LPS and then stimulated with nigericin for 0.5 h with or without Ori. Western blot analysis of cleaved IL-1β, activated caspase-1 (P20) in culture supernatants (SN) and pro-IL-1β, pro-caspase-1 in lysates (Input) of BMDMs. c, d IL-1β (c) or TNF-α (d) production (as measured by ELISA) in SN from BMDMs primed with LPS and stimulated with nigericin for 0.5 h with or without Ori. e, f Western blot analysis (e) of cleaved IL-1β and activated caspase-1 or ELISA (f) of IL-1β in SN from BMDMs primed with LPS and stimulated with MSU, nigericin or ATP in the presence or absence of Ori (2 μM). g–i Western blot analysis of cleaved IL-1β and activated caspase-1 (g) or ELISA of IL-1β (h) or TNF−α (i) production in SN from PBMCs pretreated with Ori for 0.5 h and stimulated with LPS for 16 h. Data are expressed as mean and s.e.m (n = 6) from three independent experiments (c, d, f, h, i) or are representative of three independent experiments (b, e, g). Statistical differences were calculated by unpaired Student’s t-test: ***P < 0.001 Previous studies have shown that Ori can inhibit NF-κB activation7–9, we then examined whether Ori affected LPS-induced priming for inflammasome activation. When BMDMs were stimulated with Ori at the doses of 0.5–2 μM before or after LPS treatment, Ori could not suppress LPS-induced pro-IL-1β, NLRP3 expression and TNF-α production (Supplementary Fig. 3A–C), suggesting that Ori doesnot inhibit LPS-induced priming at the doses, which are effective for NLRP3 inhibition. Indeed, we found that the inhibitory activity of Ori on IL-1β release was about ten times more potent than its activity on TNF-α production (Supplementary Fig. 4A, B), suggesting that Ori has a robust inhibitory activity on NLRP3 inflammasome. Thus, these results indicate that Ori is a specific NLRP3 inflammasome inhibitor. Ori inhibits NLRP3 inflammasome assembly Next, we studied the mechanism of how Ori blocked NLRP3 activation. Firstly, we found that Ori could suppress nigericin-induced ASC oligomerization (Fig. 2a), an essential step for NLRP3 activation36,37, suggesting that Ori acts upstream of ASC oligomerization to suppress NLRP3 activation. Secondly, Ori could not inhibit nigericin-induced mitochondrial damage and ROS production (Supplementary Fig. 5A), which are also the upstream signaling events of NLRP3 activation16,38. Moreover, we also found that Ori could not block nigericin-induced potassium or chloride efflux (Supplementary Fig. 5B, C), another two upstream signaling events of NLRP3 activation39–41. Thus, these results indicate that Ori doesnot affect the signaling events of upstream of NLRP3.Fig. 2Ori inhibits NLRP3 inflammasome assembly by blocking NEK7–NLRP3 interaction. a Western blot analysis of cross-linked ASC in the Nonidet P-40–insoluble pellet of BMDMs stimulated with nigericin